Laboratory Interpretation: Thrombocytosis with Borderline Anemia and Inflammation
This patient requires immediate evaluation for a myeloproliferative neoplasm (MPN), specifically essential thrombocythemia (ET), given the marked thrombocytosis (856 × 10³/μL) combined with borderline low hemoglobin and elevated inflammatory markers.
Key Abnormalities Identified
The CBC reveals three critical findings:
- Marked thrombocytosis: Platelets 856 × 10³/μL (reference: 147-352) - nearly 2.5× upper limit of normal
- Borderline low hemoglobin: 12.3 g/dL (reference: 12.6-17.0) with low MCHC (31.0 g/dL)
- Elevated CRP: 31.7 mg/L (reference: 0.0-10.0) indicating significant inflammation
- Normal ESR: 17 mm (reference: 0-30)
Primary Differential Diagnosis
Essential Thrombocythemia (Most Likely)
The platelet count >450 × 10³/μL meets the threshold for thrombocytosis requiring MPN evaluation 1. The 2007 WHO criteria specify that sustained platelet count ≥450 × 10³/μL warrants investigation for ET 1. This patient's count of 856 × 10³/μL is substantially elevated and cannot be dismissed as reactive.
Reactive Thrombocytosis (Must Exclude)
The elevated CRP (31.7 mg/L) suggests active inflammation, which can cause reactive thrombocytosis 2. However, platelet counts >400 × 10³/μL have 87.8% specificity for distinguishing primary from reactive causes when evaluating for conditions like giant cell arteritis 2. Common reactive causes include:
- Iron deficiency (suggested by borderline low Hgb and low MCHC)
- Active infection or inflammation
- Malignancy
- Post-surgical state or tissue damage
Immediate Next Steps
1. Confirm Iron Status (Priority #1)
Order serum ferritin, transferrin saturation (TSAT), and iron studies immediately 3. The borderline low hemoglobin (12.3 g/dL) with low MCHC (31.0 g/dL) and normal MCV (85 fL) suggests possible iron deficiency, which is a common cause of reactive thrombocytosis 1.
Interpretation thresholds in the presence of inflammation (CRP 31.7 mg/L):
- Ferritin <100 μg/L indicates iron deficiency despite inflammation 3
- TSAT <15% confirms functional iron deficiency 4
2. Repeat CBC in 2-4 Weeks
Confirm persistent thrombocytosis - ET diagnosis requires sustained elevation 1. A single elevated platelet count, especially with concurrent inflammation, may be reactive.
3. Peripheral Blood Smear Review
Request manual review by hematology laboratory 4, 5. Look specifically for:
- Platelet size and morphology (giant platelets suggest inherited disorders, not ET)
- Red cell morphology (microcytosis, hypochromia suggest iron deficiency)
- White cell abnormalities (left shift, immature forms suggest MPN)
The smear is critical to exclude other causes - normal-sized or large platelets support ET, while consistently giant platelets (approaching RBC size) argue against it 5.
4. JAK2 Mutation Testing (If Thrombocytosis Persists)
If platelet count remains >450 × 10³/μL after treating iron deficiency and inflammation, order JAK2 V617F mutation testing 1, 6. This is the first-line molecular test for ET:
- JAK2 V617F positive in ~60% of ET cases
- If JAK2 negative, proceed to CALR and MPL mutation testing 6
5. Bone Marrow Biopsy (If MPN Suspected)
Required for definitive ET diagnosis 1. The 2007 WHO criteria mandate bone marrow showing "proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes" 1.
Clinical Context Assessment
Exclude Reactive Causes
Systematically evaluate for:
- Infection: The elevated CRP warrants infection workup if clinically indicated
- Malignancy: Age-appropriate cancer screening, especially if constitutional symptoms present
- Inflammatory conditions: Rheumatologic disorders, inflammatory bowel disease
- Recent surgery or trauma: Thrombocytosis can persist 2-3 months post-operatively
- Medications: Certain drugs can elevate platelets
Assess Thrombotic Risk
If ET is confirmed, calculate the revised International Prognostic Score of Thrombosis for ET (IPSET-thrombosis) 7, 6. Risk stratification determines need for:
- Low-dose aspirin (81-100 mg daily)
- Cytoreductive therapy (hydroxyurea first-line)
High-risk features requiring cytoreductive therapy 7:
- Age >60 years
- Prior thrombosis
- Platelet count >1,000 × 10³/μL (this patient is approaching this threshold)
- JAK2 mutation positive
Evaluate for Symptoms
Specifically ask about 6:
- Microvascular symptoms: headaches, paresthesias, erythromelalgia (burning pain in extremities)
- Thrombotic events: DVT, PE, stroke, MI
- Bleeding complications: paradoxical bleeding with extreme thrombocytosis
- Splenomegaly symptoms: early satiety, left upper quadrant pain
Management Algorithm
Step 1: Treat iron deficiency if confirmed (ferritin <100 μg/L with inflammation) - oral or IV iron replacement
Step 2: Address underlying inflammation - treat infection/inflammatory condition if identified
Step 3: Repeat CBC in 2-4 weeks after treating reversible causes
Step 4: If platelets remain >450 × 10³/μL, proceed with JAK2 testing and hematology referral
Step 5: If JAK2 positive or clinical suspicion high, bone marrow biopsy for definitive diagnosis
Critical Pitfalls to Avoid
- Do not dismiss thrombocytosis as purely reactive without excluding iron deficiency and confirming resolution after treating inflammation
- Do not delay JAK2 testing if thrombocytosis persists - early MPN diagnosis affects long-term thrombotic risk management
- Do not start aspirin empirically before confirming diagnosis - bleeding risk exists with extreme thrombocytosis
- Do not overlook the borderline anemia - this may represent early iron deficiency or bone marrow dysfunction from MPN
Summary Recommendation
Order ferritin, TSAT, and iron studies immediately. Treat iron deficiency if present. Repeat CBC in 2-4 weeks. If thrombocytosis persists (platelets >450 × 10³/μL), order JAK2 V617F mutation testing and refer to hematology for bone marrow biopsy consideration. The combination of marked thrombocytosis with borderline anemia requires systematic exclusion of both reactive causes and essential thrombocythemia 1, 6.